Program for Appropriate Technology in Health:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Program for Appropriate Technology in Health - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7573
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Program for Appropriate Technology in Health (PATH) is a non-profit organization that improves health in women and children. The organization offers vaccines, drugs, diagnostics, devices, system and service innovations, and digital health solutions. It develops diagnostics for HIV and other sexually transmitted infections, malaria, tuberculosis, epidemic and emerging diseases, women’s cancers, non communicable diseases, diabetes and neglected tropical diseases. PATH caters to governments, donors, and multilateral organizations. PATH collaborates with innovators, public and private-sector partners, governments, communities, and civil society groups to develop and introduce health solutions. The organization has operations in Belgium, Cambodia, China, Congo, Ethiopia, France, Ghana, India, Kenya, the US, and others. PATH is headquartered in Seattle, Washington, the US.

Program for Appropriate Technology in Health – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2012 to YTD 2018 9
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 11
Radboudumc and iMM Lisboa Enters Into Partnership with PATH 12
CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 13
Affinivax Enters into Development Agreement with PATH for Pneumococcal Disease 14
Mymetics Enters into Co-Development Agreement with Path Malaria Vaccine Initiative 15
Scandinavian Biopharma, PATH and University of Gothenburg Amend Agreement to Develop ETEC 16
Liquidia Technologies Extends Co-Development Agreement With PATH 17
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 18
Novavax Amends Co-Development Agreement With PATH 19
Program for Appropriate Technology in Health – Key Competitors 21
Program for Appropriate Technology in Health – Key Employees 22
Program for Appropriate Technology in Health – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Joint Venture 24
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Key Facts 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Program for Appropriate Technology in Health, Deals By Therapy Area, 2012 to YTD 2018 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2012 to YTD 2018 9
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 11
Radboudumc and iMM Lisboa Enters Into Partnership with PATH 12
CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 13
Affinivax Enters into Development Agreement with PATH for Pneumococcal Disease 14
Mymetics Enters into Co-Development Agreement with Path Malaria Vaccine Initiative 15
Scandinavian Biopharma, PATH and University of Gothenburg Amend Agreement to Develop ETEC 16
Liquidia Technologies Extends Co-Development Agreement With PATH 17
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 18
Novavax Amends Co-Development Agreement With PATH 19
Program for Appropriate Technology in Health, Key Competitors 21
Program for Appropriate Technology in Health, Key Employees 22
Program for Appropriate Technology in Health, Other Locations 23
Program for Appropriate Technology in Health, Subsidiaries 24
Program for Appropriate Technology in Health, Joint Venture 24

List of Figures
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Program for Appropriate Technology in Health:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Animal Husbandry Industry Co Ltd (600195):企業の財務・戦略的SWOT分析
    China Animal Husbandry Industry Co Ltd (600195) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Panoramic Resources Ltd:企業の戦略・SWOT・財務情報
    Panoramic Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Panoramic Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • RWE AG (RWE):石油・ガス:M&Aディール及び事業提携情報
    Summary RWE AG (RWE) is an energy company. It has presence in the energy value chain, from lignite production and electricity generation, to energy trading and operation of distribution networks, and supply of electricity, gas and energy solutions. The company produces electricity using conventional …
  • Tejas Networks Ltd (TEJASNET):企業の財務・戦略的SWOT分析
    Tejas Networks Ltd (TEJASNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Akorn Inc (AKRX)-製薬・医療分野:企業M&A・提携分析
    Summary Akorn Inc (Akorn) is a pharmaceutical company which carries out the development, manufacturing and commercialization of generic and branded prescription pharmaceuticals and branded and over-the-counter consumer health products and animal health pharmaceuticals. The company offers its product …
  • Viterra Inc.:企業のM&A・事業提携・投資動向
    Viterra Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Viterra Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Landauer Inc (LDR):企業の財務・戦略的SWOT分析
    Summary Landauer Inc (Landauer), a subsidiary of Fortive Corp, is a medical device company that manufactures and distributes integrated radiation safety products. The company provides professional medical physics, occupational radiation monitoring, and medical products. Its products include dosimete …
  • Mizuno Corporation (8022):企業の財務・戦略的SWOT分析
    Mizuno Corporation (8022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • PHX Energy Services Corp (PHX):企業の財務・戦略的SWOT分析
    Summary PHX Energy Services Corp (PHX Energy), formerly Phoenix Technology Income Fund is an energy service company that manufactures, designs, and engineers directional drilling technologies. The corporation’s equipment includes RADD, P-360 MWD, 360-CV MWD, E-360 MWD, 360 RWD, and performance motor …
  • Investor AB (INVE B):企業の財務・戦略的SWOT分析
    Investor AB (INVE B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Ineos Group AG:企業の戦略的SWOT分析
    Ineos Group AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Labrador Iron Mines Holdings Limited:企業の戦略・SWOT・財務情報
    Labrador Iron Mines Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Labrador Iron Mines Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Humana Inc.:企業の戦略・SWOT・財務分析
    Humana Inc. - Strategy, SWOT and Corporate Finance Report Summary Humana Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Central Iowa Power Cooperative:企業の戦略的SWOT分析
    Central Iowa Power Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Korea Gas Corp (036460)-石油・ガス分野:企業M&A・提携分析
    Summary Korea Gas Corp (KOGAS) is a vertically integrated natural gas company active in upstream midstream and downstream segments of natural gas industry. It explores, produces and distributes natural gas. The company also purifies and sells by-products; imports and exports natural gas and liquefie …
  • ZAPPALLAS, Inc. (3770):企業の財務・戦略的SWOT分析
    ZAPPALLAS, Inc. (3770) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Oncgnostics GmbH:企業の製品パイプライン分析
    Summary Oncgnostics GmbH (Oncgnostics) is an in-vitro diagnostic company that offers development of in-vitro diagnostic tests for the therapeutics area of cancer. The company offers pipeline products such as GynTect technology a system based on the detection of epigenetic biomarkers mainly in the me …
  • HUYA Bioscience International LLC-製薬・医療分野:企業M&A・提携分析
    Summary HUYA Bioscience International LLC (HUYA) is a developer of early and late stage drug candidates. The company’s pipeline products comprise HBI-8000, HBI-3000, and HBI-3802. Its HBI-8000 is a novel oral inhibitor of histone deacetylases; HBI-3000 is a channel blocker for the treatment of arrhy …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG, BAY 1905254, COM902 and TIGIT; and CGEN-XXXX/Myeloid and autoimmune diseases …
  • Tikcro Technologies Ltd (TIKRF):企業の財務・戦略的SWOT分析
    Summary Tikcro Technologies Ltd (Tikcro) is a biotechnology company that discovers, develops, manufactures and markets antibodies. The company undertakes clinical trials for its pipeline products PD1, PDL1, PDL2, TIGIT and CTLA-4 products, among others. Tikcro products are based on 3D antigens desig …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆